Official registry condition

Recurrent Prostate Cancer peptide trials

3 selected ClinicalTrials.gov records carrying the official condition label Recurrent Prostate Cancer. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

3 selected records.

Connected peptides

1 profiles.

Registry update years

2016–2026 in selected records.

Indication intelligence

Selected evidence landscape

Connected profiles1

Exact peptide identities attached to retained registry observations carrying this condition label.

Trial phases1

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses2

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 46 selected PubMed records and 24 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Recurrent Prostate Cancer unless their own cited source says so.

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00454571

PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
February 10, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01750398

PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
December 5, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06378866

PeptideScanner retained ClinicalTrials.gov record NCT06378866 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
July 20, 2026
Evidence lane
Clinical trials

Attributed registry records

Selected records

All trial facets →